RT @KelvinS_MD: I’m honored to be selected as a finalist for the Elizabeth Barrett-Conor early career award at #AHA25! Deeply grateful for….

RT @aklfahed: 4.6 million patients with a first MI (2017–2022). Prior to MI: .50.5% had no documented symptoms.18.0% had no SMuRFs.22.2% di….

Generate videos in just a few seconds. Try Grok Imagine, free for a limited time.

RT @pnatarajanmd: Our study led by R. Bhattacharya & @cmarnell92 shows that, when simultaneously considering clinical, laboratory, and gene….

RT @skathire: Today, we are thrilled to announce that @VerveTx has entered into a definitive agreement to be acquired by @EliLillyandCo. Fr….

RT @pnatarajanmd: HUGE congrats to graduating @MGHCVFellows @tigerstatdoc @SumeetKhetarpal, both 🌟 preventive cardiologist-scientists, for….

RT @skathire: @VerveTx team is thrilled today to present initial data from the Heart-2 Phase 1b clinical trial of VERVE-102, an in vivo bas….

RT @KelvinS_MD: Defended my master’s thesis few days ago! Couldn’t have reached this point without continuous guidance from my mentor @aklf….

Fantastic collaboration across multiple institutions. @joeltramo, Liam Gaziano, Alice Zheng, Dolphurs Hayes, @CarlosGongoraMD @FinnGen_FI, Seung Hoan Choi @AranyLab @dineshpmcc1 @aklfahed @sarma_amy @tomasneilan. H/t @patrick_ellinor and @amitvkhera for catalyzing these efforts.

**Conclusions**.(1) PPCM, ALCM, and CCM are genetically similar to DCM, but are precipitated by distinct factors (pregnancy, alcohol, cancer chemotherapy). (2) Genetic factors may help identify those at risk, especially in the absence of clinical signs.

PPCM, ALCM, and CCM can be tough to predict in the clinical setting. In fact, in our study, most cases lacked clear antecedent clinical risk factors. Genetic risk may be the only clue that someone is predisposed. 🧬

As established, monogenic DCM variants (i.e. TTN truncating variants) were strongly linked to PPCM, ALCM, and CCM, but accounted for <10% of all cases. High polygenic risk was found in ~40% of cases and conferred ~3x odds of developing cardiomyopathy.

Distributions of the DCM polygenic score showed a clear upshift among PPCM, ALCM, and CCM cases compared to controls, on par with (if not more pronounced than) the enrichment seen in DCM itself

Despite modest case numbers, DCM polygenic risk was strongly associated with all 3 secondary cardiomyopathies across the 3 studies. • PPCM: OR = 1.88 per SD increase in PRS (p = 0.001).• ALCM: OR = 1.38 (p = 1.46E-07).• CCM: OR = 1.58 (p = 2.97E-06)

We first coalesced cases of PPCM, ALCM, and CCM from 3 large biobanks:. • Mass General Brigham Biobank (N = 113 cases, *chart-validated*). • UK Biobank (N = 105 cases). • FinnGen (N = 197 cases).

Rare, monogenic variants linked to DCM (like truncating variants in TTN) are prevalent in PPCM, ALCM, and CCM, present in ~10-15% of all cases. Could common genetic (polygenic) risk for DCM also contribute to these conditions?

Now on medRxiv, we explore the genetic similarity between dilated cardiomyopathy (DCM) and peripartum, alcohol-induced, and cancer therapy-related cardiomyopathies (PPCM, ALCM, CCM). Led by star trio @DimitriMaamari, @kiranbiddinger, and @JurgensSean.

RT @yurikim_mdphd: Excited to share our latest publication where we identified a novel and essential role of TTN enhancer. Thanks to @Meraj….

RT @skathire: Exciting to see a series of human genetic observations we made a few years back now moving into therapeutic space. ALK7 loss….

RT @pnatarajanmd: Delighted to share our study by @tigerstatdoc with @aklfahed on adding in a CAD polygenic risk score to clinical factors….

RT @EricTopol: The relationship of high polygenic risk scores to coronary artery disease disease for extent of atherosclerosis and presenta….